CARDIAC CARE
  • Animeal

CARDIAC CARE

Ipca Mmf-500 Tablet

Ipca Mmf-500 Tablet

By IPCA

₹ 540
-10% off ₹ 540 M.R.P: ₹ 600
Unlock Unbeatable offers! WhatsApp us now
Tax included. Shipping calculated at checkout.

Out of Stock

Pack - 10Tabs
Expires on or after: Feb, 2027
Title

Check Availability

Rapid 3-4 Day Delivery,Tiny Extra Fee!

  • AnimealPet Safe
  • AnimealBest Quality
  • AnimealFast Delivery
  • AnimealSecure Payment
View full details

IPCA MMF Tablets are a critical product in our VETERINARY IMMUNOSUPPRESSANT THERAPY category. Manufactured by IPCA Laboratories Ltd. one of India's most respected and globally certified pharmaceutical manufacturers under strict WHO-GMP and Schedule M Good Manufacturing Practice standards, Mycophenolate Mofetil is a selective, potent inhibitor of inosine monophosphate dehydrogenase (IMPDH) the rate-limiting enzyme in the de novo purine synthesis pathway that lymphocytes uniquely depend upon for proliferation. By selectively suppressing both T-lymphocyte and B-lymphocyte proliferation without the broader metabolic toxicity profile of older immunosuppressants, MMF offers veterinary specialists a more targeted, relatively lymphocyte-selective immunosuppressive option for managing complex immune-mediated conditions in companion animals. With IPCA MMF, veterinary specialists can rely on a pharmaceutically consistent, clinically validated, and cost-accessible source of this critical therapeutic agent for their most challenging immunological cases.

Composition:

IPCA MMF Tablets are formulated with a precise pharmaceutical-grade composition for consistent and reliable oral bioavailability:

  • Mycophenolate Mofetil 500mg (Active Ingredient): a prodrug that is rapidly and completely hydrolysed after oral absorption to its active metabolite Mycophenolic Acid (MPA), which selectively and reversibly inhibits IMPDH the critical enzyme in lymphocyte de novo purine synthesis. Since lymphocytes lack the salvage pathway for purine synthesis that most other cell types possess, they are uniquely dependent on IMPDH activity for proliferation making MPA selectively cytostatic for both T and B lymphocytes with relative sparing of other rapidly dividing cell populations. This lymphocyte-selective mechanism is what distinguishes MMF from older, less selective immunosuppressants such as azathioprine and cyclophosphamide
  • Microcrystalline Cellulose (MCC): a pharmaceutical-grade binder and disintegrant ensuring tablet structural integrity, consistent hardness, and reliable and predictable disintegration profile for uniform drug release upon oral administration
  • Croscarmellose Sodium: a pharmaceutical superdisintegrant that facilitates rapid and complete tablet disintegration in the gastrointestinal tract, supporting consistent and reproducible Mycophenolate absorption and bioavailability across individual patients
  • Povidone K-30 (PVP): a pharmaceutical granulation binder ensuring uniform distribution of the active ingredient throughout the tablet matrix, supporting dose precision and batch-to-batch manufacturing consistency
  • Magnesium Stearate (Lubricant): a pharmaceutical-grade tablet lubricant ensuring manufacturing process consistency and preventing tablet sticking during high-volume production
  • Film Coating (HPMC, PEG, Titanium Dioxide): a standard film coat that improves tablet swallowability, protects the active ingredient from environmental moisture and light degradation, and provides the characteristic white tablet appearance that facilitates product identification

Selective Lymphocyte-Targeted Immunosuppression: the de novo purine synthesis inhibition mechanism selectively targets the lymphocyte populations driving immune-mediated pathology with relative sparing of other cell lineages providing meaningful immunosuppression with a comparatively favourable selectivity profile versus older agents such as azathioprine and cyclophosphamide

Management of Immune-Mediated Haemolytic Anaemia (IMHA): used as a steroid-sparing adjunctive immunosuppressant in canine IMHA cases refractory to prednisolone monotherapy, helping achieve haematological remission while reducing the cumulative corticosteroid burden and its associated adverse effects

Immune-Mediated Thrombocytopenia (ITP): employed as part of multi-drug immunosuppressive protocols in severe or refractory canine ITP cases to accelerate platelet count recovery and reduce relapse frequency

Protein-Losing Nephropathy & Protein-Losing Enteropathy: used in immunosuppressive protocols for immune-mediated glomerulonephritis and inflammatory bowel disease-associated protein-losing conditions in dogs and cats under nephrology and gastroenterology specialist supervision

Meningoencephalomyelitis of Unknown Aetiology (MUA/MUE): incorporated into multi-drug immunosuppressive protocols for granulomatous meningoencephalomyelitis (GME) and necrotising encephalitis under veterinary neurology specialist oversight

Refractory Immune-Mediated Skin Diseases: used off-label by veterinary dermatologists for pemphigus foliaceus, discoid lupus erythematosus, and other severe immune-mediated dermatoses refractory to first-line corticosteroid and ciclosporin therapy

Organ Transplant Rejection Prophylaxis (Experimental): used in experimental and academic veterinary transplantation protocols at veterinary teaching hospitals for renal allograft rejection prevention in dogs

Steroid-Sparing Protocol Component: its use as a corticosteroid-sparing adjunct agent allows meaningful reduction of prednisolone doses in long-term immunosuppressive management, significantly reducing the cumulative corticosteroid adverse effect burden including iatrogenic hyperadrenocorticism, gastrointestinal ulceration, and opportunistic infection risk

For administration under the prescription and active clinical supervision of a veterinary internal medicine specialist, veterinary dermatologist, or veterinary neurologist only. Administer orally with food to reduce gastrointestinal adverse effects. Tablets may be split for dose adjustment but should not be crushed, as this releases the active ingredient in a form that poses significant inhalation and mucosal contact risk to handlers. Gloves must be worn by all personnel handling and administering MMF tablets. Pregnant staff must never handle MMF under any circumstances.

Storage Advice:

Store between 15°C and 30°C in a cool, dry place. Protect from direct light and moisture. Keep in original blister packaging until point of use. Do not crush or split tablets without appropriate PPE including gloves and eye protection. Pregnant personnel must never handle this product. Dispose of unused tablets and strips responsibly in accordance with pharmaceutical waste disposal regulations. Do not use after the expiry date printed on the strip.

About the Brand:

IPCA Laboratories Ltd. is one of India's most respected and globally recognised pharmaceutical manufacturers, established in 1949 and operating across more than 100 countries worldwide. With manufacturing facilities holding US FDA, UK MHRA, WHO-GMP, and European EDQM certifications, IPCA maintains the highest international standards of pharmaceutical quality, consistency, and safety across their extensive generic and branded pharmaceutical portfolio. Their Mycophenolate Mofetil formulation reflects IPCA's unwavering commitment to delivering pharmacopoeial-grade active pharmaceutical ingredients at consistent potency and purity giving veterinary specialists the confidence that the drug they prescribe is the drug their patient reliably receives in every tablet, from every batch, without compromise.

Disclaimer:

IPCA MMF Tablets (Mycophenolate Mofetil 500mg) are a Schedule H1 prescription-only pharmaceutical product for use exclusively in veterinary specialist clinical settings under the active supervision and prescription of a registered veterinary specialist. This product is procured and dispensed solely for registered veterinary clinics, teaching hospitals, and specialist referral practices holding valid veterinary practice registration. It is absolutely not available for retail sale, over-the-counter dispensing, or home administration under any circumstance. Mycophenolate Mofetil carries a significant adverse effect profile including bone marrow suppression, opportunistic infections, gastrointestinal haemorrhage, hepatotoxicity, and teratogenicity all of which require specialist clinical monitoring to detect and manage safely. VetSpecialist Pro supports evidence-based specialist veterinary care but does not replace the clinical judgement, prescription authority, or monitoring responsibility of the treating veterinary specialist. Inappropriate use of this product in animals without proper specialist oversight and haematological monitoring could result in severe, irreversible, and potentially fatal adverse outcomes.

Q: What is the primary mechanism of action of Mycophenolate Mofetil in dogs and cats?
Mycophenolate Mofetil is a prodrug that is rapidly hydrolysed after oral absorption to its pharmacologically active form, Mycophenolic Acid (MPA). MPA selectively and reversibly inhibits Inosine Monophosphate Dehydrogenase (IMPDH) the rate-limiting enzyme in the de novo purine synthesis pathway. Because lymphocytes uniquely lack the alternative salvage pathway for purine synthesis that most other cell types possess, they are entirely dependent on IMPDH activity for DNA replication and cell proliferation. By selectively blocking this pathway, MPA exerts a potent and relatively lymphocyte-selective cytostatic effect on both T and B lymphocytes the primary cellular mediators of immune-mediated pathology with comparatively less toxicity to other rapidly dividing cell populations.
Q: What mandatory monitoring is required during MMF therapy in companion animals?
Haematological and biochemical monitoring is non-negotiable throughout the entire course of MMF therapy. A baseline CBC, serum biochemistry panel (including hepatic enzymes and renal parameters), and urinalysis must be established before initiating treatment. During the first 3 months of therapy, CBC should be repeated every 2 to 4 weeks to detect early myelosuppression, neutropenia, or anaemia. After 3 months of stable therapy, monthly monitoring is the minimum acceptable standard. In cats, who are at higher risk of MMF-induced myelosuppression than dogs, more frequent monitoring at 2-weekly intervals is strongly recommended throughout the treatment course. Therapy must be discontinued immediately if neutrophil counts fall below the critical threshold or if clinical signs consistent with opportunistic infection, hepatotoxicity, or haemorrhagic gastroenteritis develop.
Q: Can MMF be combined with prednisolone and ciclosporin in multi-drug immunosuppressive protocols?
Yes MMF is most commonly used as a component of multi-drug immunosuppressive protocols in combination with prednisolone and, in some cases, ciclosporin. Its complementary and non-overlapping mechanism of action makes it an effective adjunct to corticosteroids in steroid-sparing protocols, allowing meaningful prednisolone dose reduction while maintaining adequate immunosuppression. However, MMF must never be combined with azathioprine both agents are myelosuppressive by different mechanisms, and their combination carries a significantly elevated risk of severe, potentially life-threatening bone marrow suppression. All multi-drug immunosuppressive protocols involving MMF should be designed and supervised exclusively by a veterinary internal medicine specialist.
Q: Why is extra caution required when using MMF in cats compared to dogs?
Cats demonstrate a significantly higher sensitivity to the myelosuppressive adverse effects of Mycophenolate Mofetil compared to dogs, likely due to pharmacokinetic differences in MMF absorption and MPA plasma protein binding in the feline species. Clinical experience and published veterinary case reports consistently demonstrate that cats are at substantially greater risk of developing severe neutropenia, anaemia, and bone marrow suppression at doses that are well tolerated in dogs. As a result, MMF is used at lower doses and once-daily frequency in cats, with mandatory bi-weekly CBC monitoring throughout the treatment course more frequent than the monitoring interval typically employed in dogs on equivalent therapy.
Q: How can registered veterinary clinics and specialist practices procure IPCA MMF 500mg Tablets through Animeal?
Registered veterinary clinics, specialist referral practices, and veterinary teaching hospitals can procure IPCA MMF 500mg Tablets through Animeal dedicated specialist pharmaceutical procurement channel. Please contact our procurement team with your valid veterinary practice registration certificate, GST documentation, and treating veterinary specialist's prescription to initiate your procurement account. Animeal ensures reliable, compliant, temperature-appropriate, and fully documented pharmaceutical delivery to your registered practice address so your most complex immunological cases always have access to the specialist-grade pharmacotherapy they require.
Ipca Mmf-500 Tablet - Animeal
Rx Required
🚚 FREE delivery on orders above ₹499
10 DaysEasy Returns
100%Authentic
SecurePayments
CARDIAC CARE

Ipca Mmf-500 Tablet

By IPCA
₹ 540.00
You save ₹ 60.00 (10%)
MRP ₹ 600.00 (Incl. taxes)

Out of Stock

Expires on or after: Jan, 2026
Size
₹ 540.00
MRP ₹ 600.00  10% OFF
1
Check Availability

IPCA MMF Tablets are a critical product in our VETERINARY IMMUNOSUPPRESSANT THERAPY category. Manufactured by IPCA Laboratories Ltd. one of India's most respected and globally certified pharmaceutical manufacturers under strict WHO-GMP and Schedule M Good Manufacturing Practice standards, Mycophenolate Mofetil is a selective, potent inhibitor of inosine monophosphate dehydrogenase (IMPDH) the rate-limiting enzyme in the de novo purine synthesis pathway that lymphocytes uniquely depend upon for proliferation. By selectively suppressing both T-lymphocyte and B-lymphocyte proliferation without the broader metabolic toxicity profile of older immunosuppressants, MMF offers veterinary specialists a more targeted, relatively lymphocyte-selective immunosuppressive option for managing complex immune-mediated conditions in companion animals. With IPCA MMF, veterinary specialists can rely on a pharmaceutically consistent, clinically validated, and cost-accessible source of this critical therapeutic agent for their most challenging immunological cases.

Composition:

IPCA MMF Tablets are formulated with a precise pharmaceutical-grade composition for consistent and reliable oral bioavailability:

  • Mycophenolate Mofetil 500mg (Active Ingredient): a prodrug that is rapidly and completely hydrolysed after oral absorption to its active metabolite Mycophenolic Acid (MPA), which selectively and reversibly inhibits IMPDH the critical enzyme in lymphocyte de novo purine synthesis. Since lymphocytes lack the salvage pathway for purine synthesis that most other cell types possess, they are uniquely dependent on IMPDH activity for proliferation making MPA selectively cytostatic for both T and B lymphocytes with relative sparing of other rapidly dividing cell populations. This lymphocyte-selective mechanism is what distinguishes MMF from older, less selective immunosuppressants such as azathioprine and cyclophosphamide
  • Microcrystalline Cellulose (MCC): a pharmaceutical-grade binder and disintegrant ensuring tablet structural integrity, consistent hardness, and reliable and predictable disintegration profile for uniform drug release upon oral administration
  • Croscarmellose Sodium: a pharmaceutical superdisintegrant that facilitates rapid and complete tablet disintegration in the gastrointestinal tract, supporting consistent and reproducible Mycophenolate absorption and bioavailability across individual patients
  • Povidone K-30 (PVP): a pharmaceutical granulation binder ensuring uniform distribution of the active ingredient throughout the tablet matrix, supporting dose precision and batch-to-batch manufacturing consistency
  • Magnesium Stearate (Lubricant): a pharmaceutical-grade tablet lubricant ensuring manufacturing process consistency and preventing tablet sticking during high-volume production
  • Film Coating (HPMC, PEG, Titanium Dioxide): a standard film coat that improves tablet swallowability, protects the active ingredient from environmental moisture and light degradation, and provides the characteristic white tablet appearance that facilitates product identification

Selective Lymphocyte-Targeted Immunosuppression: the de novo purine synthesis inhibition mechanism selectively targets the lymphocyte populations driving immune-mediated pathology with relative sparing of other cell lineages providing meaningful immunosuppression with a comparatively favourable selectivity profile versus older agents such as azathioprine and cyclophosphamide

Management of Immune-Mediated Haemolytic Anaemia (IMHA): used as a steroid-sparing adjunctive immunosuppressant in canine IMHA cases refractory to prednisolone monotherapy, helping achieve haematological remission while reducing the cumulative corticosteroid burden and its associated adverse effects

Immune-Mediated Thrombocytopenia (ITP): employed as part of multi-drug immunosuppressive protocols in severe or refractory canine ITP cases to accelerate platelet count recovery and reduce relapse frequency

Protein-Losing Nephropathy & Protein-Losing Enteropathy: used in immunosuppressive protocols for immune-mediated glomerulonephritis and inflammatory bowel disease-associated protein-losing conditions in dogs and cats under nephrology and gastroenterology specialist supervision

Meningoencephalomyelitis of Unknown Aetiology (MUA/MUE): incorporated into multi-drug immunosuppressive protocols for granulomatous meningoencephalomyelitis (GME) and necrotising encephalitis under veterinary neurology specialist oversight

Refractory Immune-Mediated Skin Diseases: used off-label by veterinary dermatologists for pemphigus foliaceus, discoid lupus erythematosus, and other severe immune-mediated dermatoses refractory to first-line corticosteroid and ciclosporin therapy

Organ Transplant Rejection Prophylaxis (Experimental): used in experimental and academic veterinary transplantation protocols at veterinary teaching hospitals for renal allograft rejection prevention in dogs

Steroid-Sparing Protocol Component: its use as a corticosteroid-sparing adjunct agent allows meaningful reduction of prednisolone doses in long-term immunosuppressive management, significantly reducing the cumulative corticosteroid adverse effect burden including iatrogenic hyperadrenocorticism, gastrointestinal ulceration, and opportunistic infection risk

For administration under the prescription and active clinical supervision of a veterinary internal medicine specialist, veterinary dermatologist, or veterinary neurologist only. Administer orally with food to reduce gastrointestinal adverse effects. Tablets may be split for dose adjustment but should not be crushed, as this releases the active ingredient in a form that poses significant inhalation and mucosal contact risk to handlers. Gloves must be worn by all personnel handling and administering MMF tablets. Pregnant staff must never handle MMF under any circumstances.

Storage Advice:

Store between 15°C and 30°C in a cool, dry place. Protect from direct light and moisture. Keep in original blister packaging until point of use. Do not crush or split tablets without appropriate PPE including gloves and eye protection. Pregnant personnel must never handle this product. Dispose of unused tablets and strips responsibly in accordance with pharmaceutical waste disposal regulations. Do not use after the expiry date printed on the strip.

About the Brand:

IPCA Laboratories Ltd. is one of India's most respected and globally recognised pharmaceutical manufacturers, established in 1949 and operating across more than 100 countries worldwide. With manufacturing facilities holding US FDA, UK MHRA, WHO-GMP, and European EDQM certifications, IPCA maintains the highest international standards of pharmaceutical quality, consistency, and safety across their extensive generic and branded pharmaceutical portfolio. Their Mycophenolate Mofetil formulation reflects IPCA's unwavering commitment to delivering pharmacopoeial-grade active pharmaceutical ingredients at consistent potency and purity giving veterinary specialists the confidence that the drug they prescribe is the drug their patient reliably receives in every tablet, from every batch, without compromise.

Disclaimer:

IPCA MMF Tablets (Mycophenolate Mofetil 500mg) are a Schedule H1 prescription-only pharmaceutical product for use exclusively in veterinary specialist clinical settings under the active supervision and prescription of a registered veterinary specialist. This product is procured and dispensed solely for registered veterinary clinics, teaching hospitals, and specialist referral practices holding valid veterinary practice registration. It is absolutely not available for retail sale, over-the-counter dispensing, or home administration under any circumstance. Mycophenolate Mofetil carries a significant adverse effect profile including bone marrow suppression, opportunistic infections, gastrointestinal haemorrhage, hepatotoxicity, and teratogenicity all of which require specialist clinical monitoring to detect and manage safely. VetSpecialist Pro supports evidence-based specialist veterinary care but does not replace the clinical judgement, prescription authority, or monitoring responsibility of the treating veterinary specialist. Inappropriate use of this product in animals without proper specialist oversight and haematological monitoring could result in severe, irreversible, and potentially fatal adverse outcomes.

Q: What is the primary mechanism of action of Mycophenolate Mofetil in dogs and cats?
Mycophenolate Mofetil is a prodrug that is rapidly hydrolysed after oral absorption to its pharmacologically active form, Mycophenolic Acid (MPA). MPA selectively and reversibly inhibits Inosine Monophosphate Dehydrogenase (IMPDH) the rate-limiting enzyme in the de novo purine synthesis pathway. Because lymphocytes uniquely lack the alternative salvage pathway for purine synthesis that most other cell types possess, they are entirely dependent on IMPDH activity for DNA replication and cell proliferation. By selectively blocking this pathway, MPA exerts a potent and relatively lymphocyte-selective cytostatic effect on both T and B lymphocytes the primary cellular mediators of immune-mediated pathology with comparatively less toxicity to other rapidly dividing cell populations.
Q: What mandatory monitoring is required during MMF therapy in companion animals?
Haematological and biochemical monitoring is non-negotiable throughout the entire course of MMF therapy. A baseline CBC, serum biochemistry panel (including hepatic enzymes and renal parameters), and urinalysis must be established before initiating treatment. During the first 3 months of therapy, CBC should be repeated every 2 to 4 weeks to detect early myelosuppression, neutropenia, or anaemia. After 3 months of stable therapy, monthly monitoring is the minimum acceptable standard. In cats, who are at higher risk of MMF-induced myelosuppression than dogs, more frequent monitoring at 2-weekly intervals is strongly recommended throughout the treatment course. Therapy must be discontinued immediately if neutrophil counts fall below the critical threshold or if clinical signs consistent with opportunistic infection, hepatotoxicity, or haemorrhagic gastroenteritis develop.
Q: Can MMF be combined with prednisolone and ciclosporin in multi-drug immunosuppressive protocols?
Yes MMF is most commonly used as a component of multi-drug immunosuppressive protocols in combination with prednisolone and, in some cases, ciclosporin. Its complementary and non-overlapping mechanism of action makes it an effective adjunct to corticosteroids in steroid-sparing protocols, allowing meaningful prednisolone dose reduction while maintaining adequate immunosuppression. However, MMF must never be combined with azathioprine both agents are myelosuppressive by different mechanisms, and their combination carries a significantly elevated risk of severe, potentially life-threatening bone marrow suppression. All multi-drug immunosuppressive protocols involving MMF should be designed and supervised exclusively by a veterinary internal medicine specialist.
Q: Why is extra caution required when using MMF in cats compared to dogs?
Cats demonstrate a significantly higher sensitivity to the myelosuppressive adverse effects of Mycophenolate Mofetil compared to dogs, likely due to pharmacokinetic differences in MMF absorption and MPA plasma protein binding in the feline species. Clinical experience and published veterinary case reports consistently demonstrate that cats are at substantially greater risk of developing severe neutropenia, anaemia, and bone marrow suppression at doses that are well tolerated in dogs. As a result, MMF is used at lower doses and once-daily frequency in cats, with mandatory bi-weekly CBC monitoring throughout the treatment course more frequent than the monitoring interval typically employed in dogs on equivalent therapy.
Q: How can registered veterinary clinics and specialist practices procure IPCA MMF 500mg Tablets through Animeal?
Registered veterinary clinics, specialist referral practices, and veterinary teaching hospitals can procure IPCA MMF 500mg Tablets through Animeal dedicated specialist pharmaceutical procurement channel. Please contact our procurement team with your valid veterinary practice registration certificate, GST documentation, and treating veterinary specialist's prescription to initiate your procurement account. Animeal ensures reliable, compliant, temperature-appropriate, and fully documented pharmaceutical delivery to your registered practice address so your most complex immunological cases always have access to the specialist-grade pharmacotherapy they require.
Ipca Mmf-500 Tablet
₹ 540.00
₹ 600.00  10% OFF

Frequently Asked Questions

What is the primary mechanism of action of Mycophenolate Mofetil in dogs and cats?

Mycophenolate Mofetil is a prodrug that is rapidly hydrolysed after oral absorption to its pharmacologically active form, Mycophenolic Acid (MPA). MPA selectively and reversibly inhibits Inosine Monophosphate Dehydrogenase (IMPDH) the rate-limiting enzyme in the de novo purine synthesis pathway. Because lymphocytes uniquely lack the alternative salvage pathway for purine synthesis that most other cell types possess, they are entirely dependent on IMPDH activity for DNA replication and cell proliferation. By selectively blocking this pathway, MPA exerts a potent and relatively lymphocyte-selective cytostatic effect on both T and B lymphocytes the primary cellular mediators of immune-mediated pathology with comparatively less toxicity to other rapidly dividing cell populations.

What mandatory monitoring is required during MMF therapy in companion animals?

Haematological and biochemical monitoring is non-negotiable throughout the entire course of MMF therapy. A baseline CBC, serum biochemistry panel (including hepatic enzymes and renal parameters), and urinalysis must be established before initiating treatment. During the first 3 months of therapy, CBC should be repeated every 2 to 4 weeks to detect early myelosuppression, neutropenia, or anaemia. After 3 months of stable therapy, monthly monitoring is the minimum acceptable standard. In cats, who are at higher risk of MMF-induced myelosuppression than dogs, more frequent monitoring at 2-weekly intervals is strongly recommended throughout the treatment course. Therapy must be discontinued immediately if neutrophil counts fall below the critical threshold or if clinical signs consistent with opportunistic infection, hepatotoxicity, or haemorrhagic gastroenteritis develop.

Can MMF be combined with prednisolone and ciclosporin in multi-drug immunosuppressive protocols?

Yes MMF is most commonly used as a component of multi-drug immunosuppressive protocols in combination with prednisolone and, in some cases, ciclosporin. Its complementary and non-overlapping mechanism of action makes it an effective adjunct to corticosteroids in steroid-sparing protocols, allowing meaningful prednisolone dose reduction while maintaining adequate immunosuppression. However, MMF must never be combined with azathioprine both agents are myelosuppressive by different mechanisms, and their combination carries a significantly elevated risk of severe, potentially life-threatening bone marrow suppression. All multi-drug immunosuppressive protocols involving MMF should be designed and supervised exclusively by a veterinary internal medicine specialist.

Why is extra caution required when using MMF in cats compared to dogs?

Cats demonstrate a significantly higher sensitivity to the myelosuppressive adverse effects of Mycophenolate Mofetil compared to dogs, likely due to pharmacokinetic differences in MMF absorption and MPA plasma protein binding in the feline species. Clinical experience and published veterinary case reports consistently demonstrate that cats are at substantially greater risk of developing severe neutropenia, anaemia, and bone marrow suppression at doses that are well tolerated in dogs. As a result, MMF is used at lower doses and once-daily frequency in cats, with mandatory bi-weekly CBC monitoring throughout the treatment course more frequent than the monitoring interval typically employed in dogs on equivalent therapy.

How can registered veterinary clinics and specialist practices procure IPCA MMF 500mg Tablets through Animeal?

Registered veterinary clinics, specialist referral practices, and veterinary teaching hospitals can procure IPCA MMF 500mg Tablets through Animeal dedicated specialist pharmaceutical procurement channel. Please contact our procurement team with your valid veterinary practice registration certificate, GST documentation, and treating veterinary specialist's prescription to initiate your procurement account. Animeal ensures reliable, compliant, temperature-appropriate, and fully documented pharmaceutical delivery to your registered practice address so your most complex immunological cases always have access to the specialist-grade pharmacotherapy they require.
View All Questions